u/throwaway_44b1

Compared prices across two neighbouring countries and found the difference was mostly pack size once I normalised it.

did the same thing last year for a bigger number. never posted it. thank you for posting yours.

This. The published reimbursement criteria are the document to read, and most member states do publish them.

Asked a question here that turned out to be based on a mechanism confusion. Three people untangled it patiently.

read the combination arms separately from the monotherapy arms

Kept the prescription and the receipt for a claim, purely because a thread here told me to. Both were requested.

reimbursement is national, not European, and that is the whole board

vikram_asante is right about cross-border recognition being narrower than the summaries suggest.

Did the vial lot match the paperwork lot?

Do you have the trace, or only the summary?

This. Complementary mechanisms rather than more of the same is the actual argument for the pairing.

Is there any independent purity data on this compound that you have seen?

a result with no batch number is about a vial nobody can identify

Have now spent more on testing than on some of the orders.

This is why the template has a batch field. Without it the result is about a vial nobody can identify.

Yes — keep both the prescription and the receipt. Claims processes ask for both and never at a convenient moment.

Published reimbursement criteria exist in most member states and are usually available in the national language.

Adding the practical step — read your own country’s published criteria. They exist and they are definitive.

Right, and a point or two between services is ordinary. It is agreement, and every month somebody posts it as a scandal.

amylin analogue, different receptor family, different story

Kept a log purely because so few people are logging this one.

Adding the standing caveat — nothing here is approved standalone and research material is not for human use.

a prescription from one member state is not automatically valid in another

Chain of custody is why member-funded testing is worth more than a supplied certificate: the vial tested is the vial that arrived at a member’s door.

meera_oyelaran is right that the band matters more than the peak. Consistency across lots is the finding.

say which country or the thread is useless

the reimbursement criteria are published in most member states

Which receptor family are you attributing that effect to?

REDEFINE is the combination programme

Yes. Two services on the same batch is the strongest thing an individual member can produce, and it is not expensive.

Agreed that pharmacy margin regulation explains a lot of the price differences people find mysterious.

private pricing varies enormously between neighbouring countries

inter-lab variance runs a point or two, plan your outrage accordingly

Agreed — the template exists because a result without the batch and the claim is unanchored.

Agreed — authorisation is European, reimbursement is national, and almost every confused thread here misses that split.

Did the vial lot match the paperwork lot?

a shortage in one member state is not a shortage in all of them

This is the split the whole board depends on. Authorisation is European; payment is national.

Read the combination paper twice before saying anything here.

This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.

the trend across lots is worth more than any single figure

inter-lab variance runs a point or two, plan your outrage accordingly

nothing containing this is approved as a standalone product

Yes. Pack sizes differ enough that per-month price comparisons across borders need to be normalised before they mean anything.

amylin analogue, different receptor family, different story

Fourth lot from the same supplier in the log now and the band has been tight the whole way. That consistency is the actual finding.

Batch number and date of analysis?